December 13, 2024 01:59 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
UP teenager kills mother, lives with body for 5 days | At least six people including a child killed in Tamil Nadu hospital fire | Amid Atul Subhash row, SC says mere harassment is not enough to prove abetment to suicide | India's D Gukesh becomes youngest ever world champion in chess | Devendra Fadnavis meets PM Modi amid suspense over Maharashtra portfolio allocation | Congress wants to deviate the issue of Sonia Gandhi-George Soros link: JP Nadda | Bengaluru techie suicide: Atul Subhash's family demanded Rs. 10 lakh as dowry leading to my father's death, claims estranged wife | Syria rebels torch tomb of ousted president Bashar al-Assad's father | Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal
Covaxin | Bharat Biotech
Image Credit: Bharat Biotech Twitter Handle

Phase 3 trial data reveal Covaxin 77.8 pc effective against Covid19: Report

| @indiablooms | Jun 22, 2021, at 09:50 pm

New Delhi/IBNS: Indigenously made Covid-19 jab, Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against the deadly infection, according to data released from phase 3 trials conducted on 25,800 participants across India, according to media reports.

Trial data and results were studied and approved by the DCGI's Subject Expert Committee on Tuesday, said an NDTV report.

In March, the interim analysis of phase 3 results showed Covaxin was 81 per cent effective in preventing Covid-19 in people without prior infection after the second dose.

The data had also reflected that there was 100 per cent reduction in chances of hospitalisation in case of infection

With the approval of the Phase 3 data, Bharat biotech is likely to secure an EUL (Emergency Use Listing) from the World Health Organisation (WHO).

The report stated that the company is likely to hold a pre-submission meeting with the WHO authorities on Wednesday.

According to another news report, Bharat Biotech had told the government that it has already submitted 90 per cent of the documents required by the WHO.

Last month, Bharat Biotech had said that it expects to get WHO approval for Covaxin by September.

The approval from WHO will also allow export of Covaxin and facilitate easier international travel for Indian citizens who received the domestic vaccine yet to be validated by most of the foreign governments.

Covaxin was cleared for emergency use last year while it was still in clinical trials. The Centre had allowed to administer it under "restricted use in emergency situations in public interest".

DCGI's approval will also help resolve doubts as the government looks to expedite vaccination ahead of the likely third wave and protect the Indian population against mutant strains of the virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.